Abstracts tagged "patient preferences and treatment options"

Abstract Number: 1928 • 2018 ACR/ARHP Annual Meeting
Patient-Physician Communication about Medication Costs in Rheumatoid Arthritis
K. Julia Kaal¹, Nick Bansback^1,2,3, Aslam Anis^4,5 and Mark Harrison^5,6,7,8, ¹University of British Columbia, Vancouver, BC, Canada, ²St Paul's Hospital, Centre for Health Evaluation and Outcomes Sciences, Vancouver, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴University of British Columbia, School of Population and Public Health, Vancouver, BC, Canada, ⁵Centre for Health Evaluation and Outcomes Sciences, Vancouver, BC, Canada, ⁶Arthritis Research Canada, Vancouver, BC, Canada, ⁷Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁸Collaborations in Outcomes Research and Evaluation, Vancouver, BC, Canada
Background/Purpose: Patients often have to pay for prescription medications out-of-pocket and cost-related nonadherence is a recognized problem. The treatment of rheumatoid arthritis is associated with…
Abstract Number: 2329 • 2015 ACR/ARHP Annual Meeting
Describe Treatments As ‘new’ or ‘old’ at Your Peril: Influences on Patient Decision Making
Mark Harrison^1,2, Carlo Marra³ and Nick Bansback^4,5, ¹Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, ²Centre for Health Evaluation and Outcomes Sciences, St Paul's Hospital, Vancouver, BC, Canada, ³School of Pharmacy, Memorial University, St John's, NF, Canada, ⁴St. Paul's Hospital, Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ⁵School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Using an example of a new drug for rheumatoid arthritis which offers comparable effectiveness and side-effect point estimates to older drugs, we explore preferences…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].